Yusuke Sano
Overview
Explore the profile of Yusuke Sano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okada M, Suzuki E, Morizane C, Ogawa G, Sano Y, Imaoka H, et al.
Jpn J Clin Oncol
. 2025 Mar;
PMID: 40052520
Background: The JCOG1113, a multicenter, randomized phase III trial in patients with advanced/recurrent biliary tract cancer showed the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin. Although liver cirrhosis...
2.
Shibuki T, Ikeda M, Yokoyama M, Sano Y, Furuse J, Kobayashi S, et al.
Pancreatology
. 2025 Feb;
PMID: 39984379
Background/objectives: Depth of response (DpR; maximum % reduction from baseline in sum of the target lesion diameters) has demonstrated potential in predicting prognosis in several malignancies. However, its role in...
3.
Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, et al.
Jpn J Clin Oncol
. 2024 Dec;
55(3):304-310.
PMID: 39690810
The standard approach for stage IV gastric cancer is palliative chemotherapy. However, despite the advancements in various chemotherapy regimens, the prognosis remains poor, highlighting the urgent need to develop more...
4.
Hirano H, Kataoka K, Yamaguchi T, Wagner A, Shimada Y, Inomata M, et al.
Eur J Cancer
. 2024 Nov;
214:115139.
PMID: 39579641
Background: Fluoropyrimidine remains the key agent of adjuvant chemotherapy for stage III colorectal cancer (CRC). Western studies have shown that female sex is a favorable prognostic factor after surgery, but...
5.
Funauchi Y, Tsukushi S, Hiraga H, Sakamoto A, Kunisada T, Nagano A, et al.
Jpn J Clin Oncol
. 2024 Nov;
55(3):297-303.
PMID: 39500618
The optimal timing of surgery and the number of courses of perioperative chemotherapy for high-risk soft tissue sarcoma patients are still controversial. Tumour growth during neoadjuvant chemotherapy led to limb...
6.
Okuno T, Morizane C, Mizusawa J, Yanagimoto H, Kobayashi S, Imaoka H, et al.
Int J Clin Oncol
. 2024 Oct;
30(1):83-91.
PMID: 39441453
Background: Major hepatectomy (MH) can increase the risk of adverse events (AEs) owing to impaired drug metabolism due to decreased liver volume and surgical injury. Thus, we performed this subgroup...
7.
Tezuka S, Ozaka M, Furuse J, Yokoyama M, Uemura K, Sano Y, et al.
Pancreatology
. 2024 Jul;
24(6):909-916.
PMID: 39060124
Background: Early tumor shrinkage (ETS) is a prognostic predictor for patients treated with chemotherapy in colorectal cancer, although scarce studies evaluated its potential in locally advanced pancreatic cancer (LAPC). In...
8.
Sano Y, Kanai M, Morizane C, Sasaki K, Yoshimura M, Ito Y, et al.
Jpn J Clin Oncol
. 2024 Jun;
54(11):1214-1218.
PMID: 38941345
Pancreatic cancer remains a highly lethal disease with a 5-year survival proportion of <10%. Chemoradiotherapy is a treatment option for unresectable locally advanced (UR-LA) or borderline resectable (BR) pancreatic cancer,...
9.
Yamamoto S, Umeno H, Sano Y, Koremoto M, Goda Y, Kaneko Y, et al.
Int J Artif Organs
. 2024 May;
47(5):321-328.
PMID: 38738648
Performance evaluation of new dialysis membranes is primarily performed in vitro, which can lead to differences in clinical results. Currently, data on dialysis membrane performance and safety are available only...
10.
Kataoka K, Ouchi A, Suwa Y, Hirano H, Yamaguchi T, Takamizawa Y, et al.
Eur J Surg Oncol
. 2024 Apr;
50(6):108354.
PMID: 38657376
Although phase III randomized controlled trials (RCTs) represent the most robust statistical approach for answering clinical questions, they require massive expenditures in terms of time, labor, and funding. Ancillary and...